Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 291 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IVIG Clear all
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 19, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01814800
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
RI-002
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Cenntennial, Colorado • North Palm Beach, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 19, 2026, 2:28 AM EDT
Recruiting No phase listed Observational

IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy

NCT04208828
View directory record Official record
Conditions
Gastrointestinal Motility Disorder, Gastroparesis, Neuropathy
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
12 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 4 Interventional

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

NCT00722332
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepaGam B
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 19, 2026, 2:28 AM EDT
Recruiting Phase 4 Interventional

Two Dose Levels of Privigen in Pediatric CIDP

NCT03684018
View directory record Official record
Conditions
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
IgPro10
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Not listed Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925
View directory record Official record
Conditions
Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
Interventions
Gammaplex 5%
Drug
Lead sponsor
Isaac Melamed
Industry
Eligibility
4 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 19, 2026, 2:28 AM EDT
Not listed Phase 1 Interventional

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

NCT02287064
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
Intravenous Immune Globulin (IVIG)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 19, 2026, 2:28 AM EDT
Completed No phase listed Observational

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

NCT01971684
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Second Line ITP agents
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 19, 2026, 2:28 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Centennial, Colorado • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Terminated No phase listed Observational

Autoimmune Gastrointestinal Dysmotility: Symptoms, Pathogenesis and Treatment

NCT04859829
View directory record Official record
Conditions
Dysmotility Syndrome, Autoimmunity
Interventions
Current Intravenous Immunoglobulin (IVIG) treatment, No Intravenous Immunoglobulin (IVIG) treatment
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 19, 2026, 2:28 AM EDT
Recruiting Phase 2 Interventional

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06798012
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-881, HYQVIA, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Completed No phase listed Observational

Immunoglobulin G Therapy Dose Optimization

NCT04818177
View directory record Official record
Conditions
Obesity, Immune Deficiency
Interventions
Institutional standard intravenous immune globulin treatment
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

NCT04508530
View directory record Official record
Conditions
Pediatric Acute-Onset Neuropsychiatric Syndrome
Interventions
Panzyga, Placebo
Biological · Other
Lead sponsor
Octapharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 19, 2026, 2:28 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

NCT01736579
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
51 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 1 Interventional

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

NCT02878616
View directory record Official record
Conditions
Kidney Transplantation
Interventions
LFG316, IVIG
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 3 Interventional

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

NCT00001768
View directory record Official record
Conditions
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions
Intravenous immunoglobulin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 1Phase 2 Interventional

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

NCT01421212
View directory record Official record
Conditions
Hepatitis B Virus Associated Liver Disease
Interventions
Hepatitis B Immune Globulin (Boca HBVIg)
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
11
States / cities
San Francisco, California • Gainesville, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10%
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 19, 2026, 2:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954
View directory record Official record
Conditions
Primary Immunodeficiency, Common Variable Hypogammaglobulinemia, X-linked Hypogammaglobulinemia, Hypogammaglobulinemia, Immunodeficiency With Hyper-IgM, Wiskott-Aldrich Syndrome
Interventions
Gammaplex (Intravenous immunoglobulin)
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
3 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 19, 2026, 2:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

NCT04083183
View directory record Official record
Conditions
Non-Malignant Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Lapine T-Lymphocyte Immune Globulin, Total-Body Irradiation, Hematopoietic Cell Transplantation, Mycophenolate Mofetil, Sirolimus, Bone Marrow Aspiration, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 2:28 AM EDT